Imp Dermatology Meeting Next Week
by: juliusgylys
05/10/02 06:55 am
Msg: 45472 of 45481
Soceity for Investigative Dermatology will be holding meeting in 1-week. Abstracts are
available at sidnet.org Click on meetings and you will see view abstracts.
Click search on left enter in Psoriasis under keywords, may have to use search.
Xanelim has two abstracts and Biogen's Amevive (alefacept) has three or more. Each
company has an IM efficacy study (Abstract 208 Xanelim,
Abstract 822 Amevive). Each has same design and look at two doses and placebo.
Important outcomes include percentage of patients with 50% or 75% improvement.
Unfortunately, Xoma does not include 50% improvement outcome but this info is
available widely. I used 50% outcome given at recent Nasdaq investor presentation. In
short, Xanelim blows them away, here's summary, read for yourself at website. Will
post abstracts when have more time than this am.
Low Dose Xanelim, 75% Improvement: 29%
Low Dose Amevive, 75% Improvement: 12%
Low Dose Xanelim, 50% Improvement: 56%
Low Dose Amevive, 50% Improvement: 36%
High Dose Xanelim, 75% Improvement: 28%
High Dose Amevive, 75% Improvement: 21%
High Dose Xanelim, 50% Improvement: 55%
High Dose Amevive, 50% Improvement: 42%
When looking at Amevive abs, be sure to see if it's IM or IV. Their IV safety (ab 821)
is presented, but for IM safety (ab 820), no results are given, likely not available at time
of abstract submission or not good result. |
